OTCMKTS:RHHVF

Roche (RHHVF) Stock Price, News & Analysis

Roche logo
$483.84 -3.66 (-0.75%)
As of 11/16/2026 03:37 PM Eastern

About Roche Stock (OTCMKTS:RHHVF)

Advanced

Key Stats

Today's Range
$483.84
▼
$495.00
50-Day Range
$414.98
▼
$490.92
52-Week Range
$356.79
▼
$499.76
Volume
50,694 shs
Average Volume
10,999 shs
Market Capitalization
N/A
P/E Ratio
44.76
Dividend Yield
1.61%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Roche Holding AG is a Switzerland-based healthcare company that develops and supplies pharmaceutical products and diagnostic systems. Its business is organized around two primary divisions: Pharmaceuticals, which focuses on medicines for areas such as oncology, immunology, neuroscience, ophthalmology and rare diseases; and Diagnostics, which provides laboratory tests, instruments and digital solutions used for disease detection, monitoring and treatment decisions.

The company markets prescription medicines under brands that include Ocrevus, Hemlibra, Vabysmo, Tecentriq and Alecensa, as well as a broad portfolio of in-vitro diagnostic products and services. Roche also conducts research in personalized healthcare, combining diagnostic information with targeted therapies to support more individualized patient treatment.

Founded in 1896 and headquartered in Basel, Switzerland, Roche serves healthcare providers, laboratories and patients internationally through operations and distribution networks spanning numerous regions, including Europe, North America and Asia-Pacific. The company has maintained a close relationship with Genentech, its U.S.-based biotechnology subsidiary, which Roche acquired in 2009.

Roche is led by Chief Executive Officer Thomas Schinecker, who assumed the role in 2023, and Chairman Severin Schwan. The company’s shares trade on the SIX Swiss Exchange, with additional over-the-counter trading in the United States under the symbol RHHVF.

AI Generated. May Contain Errors.

Roche Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
1st Percentile Overall Score

RHHVF MarketRank™: 
0.07327471356 of 5 stars

Roche scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Roche.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Roche is 44.76, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.76.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Roche is 44.76, which means that it is trading at a more expensive P/E ratio than the Healthcare sector average P/E ratio of about 32.96.

  • Read more about Roche's valuation and earnings.
  • Percentage of Shares Shorted

  • Short Interest Ratio / Days to Cover

    Roche has a short interest ratio ("days to cover") of 433.79, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Roche has recently decreased by 3.85%, indicating that investor sentiment is improving.
  • Dividend Yield

    Roche pays a meaningful dividend of 3.21%, higher than the bottom 25% of all stocks that pay dividends.

  • Dividend Growth

    Roche does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of Roche is 72.16%. This payout ratio is at a healthy, sustainable level, below 75%.

  • Read more about Roche's dividend.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Roche this week, compared to 1 article on an average week.
  • MarketBeat Follows

    1 people have added Roche to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Roche insiders have not sold or bought any company stock.

  • Percentage Held by Institutions

    29.01% of the stock of Roche is held by institutions.

  • Read more about Roche's insider trading history.
Receive RHHVF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Roche and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

RHHVF Stock News Headlines

Roche Holding AG (RHHVF) was downgraded to a Hold Rating at UBS
You missed yesterday's deadline…
In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.tc pixel
Roche Holding AG (RHHVF) Receives a Buy from RBC Capital
See More Headlines

RHHVF Stock Analysis - Frequently Asked Questions

Roche's stock was trading at $412.9150 at the start of the year. Since then, RHHVF stock has increased by 17.2% and is now trading at $483.8399.

Shares of RHHVF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Roche investors own include NVIDIA (NVDA), Novartis (NVS), Visa (V), Pfizer (PFE), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK) and Tesla (TSLA).

Company Calendar

Today
11/16/2026
Next Earnings (Estimated)
1/28/2027

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
OTCMKTS:RHHVF
CIK
N/A
Fax
N/A
Employees
103,249
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
44.76
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

This page (OTCMKTS:RHHVF) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners